Nurix Therapeutics, Inc. (NRIX)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $2.64B
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Latest financial period: May 31, 2026
Filed with the SEC: July 9, 2026
Estimated earnings date: October 8, 2026
Profit #1452 of 1484 companies
| | May 26 | Feb 26 | Nov 25 | Aug 25 |
|---|
| ROE/ROA | 1.6% | 2.6% | 3.4% | 2.8% |
Growth #1451 of 1484 companies
Payout #1117 of 1484 companies
Safety #856 of 1484 companies
Price #1461 of 1484 companies
